Genprex Inc (GNPX)

Currency in USD
1.890
-0.120(-5.97%)
Closed·
1.880-0.010(-0.54%)
·
Trading near 52-week Low
GNPX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.8452.010
52 wk Range
1.84555.000
Key Statistics
Prev. Close
2.01
Open
2
Day's Range
1.845-2.01
52 wk Range
1.845-55
Volume
204.56K
Average Volume (3m)
721.43K
1-Year Change
-95.95%
Book Value / Share
0.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GNPX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Genprex Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Genprex Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company’s diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body’s immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

Compare GNPX to Peers and Sector

Metrics to compare
GNPX
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.5x−0.6x
PEG Ratio
0.00−0.030.00
Price/Book
5.7x1.4x2.6x
Price / LTM Sales
-181.0x3.2x
Upside (Analyst Target)
-149.6%41.8%
Fair Value Upside
Unlock−3.7%5.1%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 14, 2025
EPS / Forecast
-5.00 / -0.65
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

1.2600
ADTX
+3.28%
0.714
PPBT
-1.11%
0.2065
WORX
+1.52%
0.713
VTGN
-4.68%
0.6390
GNS
-4.34%

FAQ

What Is the Genprex (GNPX) Share Price Today?

The live Genprex share price today is 1.890

What Stock Exchange Does Genprex (GNPX) Trade On?

Genprex is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Genprex?

The stock symbol (also called a 'ticker') for Genprex is "GNPX."

What Is the Current Genprex Market Cap?

As of today, Genprex market capitalisation is 4.38M.

What Is Genprex's (GNPX) Earnings Per Share (TTM)?

The Genprex EPS is currently -37.32 (Trailing Twelve Months).

Is GNPX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Genprex moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Genprex Stock Split?

Genprex has split 2 times. (See the GNPX stock split history page for full effective split date and price information.)

How Many Employees Does Genprex Have?

Genprex has 13 employees.

What is the current trading status of Genprex (GNPX)?

As of 24 Dec 2025, Genprex (GNPX) is trading at a price of 1.890, with a previous close of 2.010. The stock has fluctuated within a day range of 1.845 to 2.010, while its 52-week range spans from 1.845 to 55.000.

What Is the GNPX Premarket Price?

GNPX's last pre-market stock price is 2.080. The pre-market share volume is 7,160.000, and the stock has decreased by 0.070, or 3.480%.

What Is the GNPX After Hours Price?

GNPX's last after hours stock price is 1.880, the stock has decreased by -0.010, or -0.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.